Literature DB >> 22250988

The prevalence of atrial fibrillation in a geographically well-defined population in northern Sweden: implications for anticoagulation prophylaxis.

P Andersson1, M Löndahl, N-J Abdon, A Terent.   

Abstract

OBJECTIVES: The aims of this study were to evaluate the community-based prevalence of atrial fibrillation (AF) in a western society using a geographically well-defined population in the northern part of Sweden as a reference and to estimate the proportion of patients eligible for oral anticoagulation (OAC) prophylactic therapy according to the stroke risk indices CHADS2 and CHA2 DS2 -VASc. Bleeding risk was assessed using the HAS-BLED score.
DESIGN: The study population was recruited from AURICULA, a Swedish national quality register for patients receiving anticoagulation treatment. All patients with the diagnosis AF in the catchment area are registered in AURICULA.
RESULTS: Of the 65 532 inhabitants in the catchment area, 1616 were diagnosed with AF (1200 cases were characterized as chronic AF). Thus, the overall prevalence of AF was 2.5%. The prevalence increased with age from 6.3% in patients over 55 years of age to 13.8% in those over 80 years. The prevalence was higher in men than in women in all age groups. Overall, 56.3% and 85.1% of the population were at high risk of stroke (≥2 points) according to CHADS2 and CHA2 DS2 -VASc, respectively. In addition, 26.9% had an increased bleeding risk according to HAS-BLED.
CONCLUSION: Within this large Caucasian population, we identified the highest community-based prevalence of AF to date. The prevalence was strongly associated with increasing age and male gender. Using CHA2 DS2 -VASc instead of CHADS(2) widened the indication for OAC prophylactic therapy of AF in this population.
© 2012 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22250988     DOI: 10.1111/j.1365-2796.2012.02519.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  13 in total

1.  Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation.

Authors:  Yutao Guo; Hao Wang; Yingchun Tian; Yutang Wang; Gregory Y H Lip
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

2.  Diagnostic accuracy and yield of screening tests for atrial fibrillation in the family practice setting: a multicentre cohort study.

Authors:  F Russell Quinn; David J Gladstone; Noah M Ivers; Roopinder K Sandhu; Lisa Dolovich; Andrea Ling; Juliet Nakamya; Chinthanie Ramasundarahettige; Paul A Frydrych; Sam Henein; Ken Ng; Valerie Congdon; Richard V Birtwhistle; Richard Ward; Jeffrey S Healey
Journal:  CMAJ Open       Date:  2018-08-02

Review 3.  Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

Authors:  K Harris; J Mant
Journal:  Int J Clin Pract       Date:  2013-04-28       Impact factor: 2.503

4.  Estimating the prevalence of atrial fibrillation in a general population using validated electronic health data.

Authors:  Johannes Norberg; Svante Bäckström; Jan-Håkan Jansson; Lars Johansson
Journal:  Clin Epidemiol       Date:  2013-12-09       Impact factor: 4.790

5.  Characterization of patients with atrial fibrillation not treated with oral anticoagulants.

Authors:  Cecilia Johansson; Lovisa Hägg; Lars Johansson; Jan-Håkan Jansson
Journal:  Scand J Prim Health Care       Date:  2014-12-03       Impact factor: 2.581

6.  European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation.

Authors:  Cheng-Hung Li; Chia-Jen Liu; Annie Y Chou; Tze-Fan Chao; Ta-Chuan Tuan; Su-Jung Chen; Kang-Ling Wang; Yenn-Jiang Lin; Shih-Lin Chang; Li-Wei Lo; Yu-Feng Hu; Fa-Po Chung; Jo-Nan Liao; Tzeng-Ji Chen; Tsu-Juey Wu; Shih-Ann Chen
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

7.  Cardioversion of atrial fibrillation does not affect obstructive sleep apnea.

Authors:  Niklas Höglund; Carin Sahlin; Milos Kesek; Steen M Jensen; Karl A Franklin
Journal:  Ups J Med Sci       Date:  2017-03-14       Impact factor: 2.384

8.  Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction--a nationwide cohort study.

Authors:  Ditte-Marie Bretler; Peter Riis Hansen; Jesper Lindhardsen; Ole Ahlehoff; Charlotte Andersson; Thomas Bo Jensen; Jakob Raunsø; Christian Torp-Pedersen; Gunnar Hilmar Gislason
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

9.  Screening for atrial fibrillation with baseline and intermittent ECG recording in an out-of-hospital population.

Authors:  Tijn Hendrikx; Rolf Hörnsten; Mårten Rosenqvist; Herbert Sandström
Journal:  BMC Cardiovasc Disord       Date:  2013-06-10       Impact factor: 2.298

10.  The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population: a prospective study.

Authors:  Li-Hua Li; Chang-Sheng Sheng; Bang-Chuan Hu; Qi-Fang Huang; Wei-Fang Zeng; Ge-Le Li; Ming Liu; Fang-Fei Wei; Lu Zhang; Yuan-Yuan Kang; Jie Song; Shuai Wang; Yan Li; Shao-Wen Liu; Ji-Guang Wang
Journal:  BMC Cardiovasc Disord       Date:  2015-05-08       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.